Bomedemstat
- Generic Name
- Bomedemstat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H34FN7O2
- CAS Number
- 1990504-34-1
- Unique Ingredient Identifier
- Y2T4ALDEAT
- Associated Conditions
- -
- Associated Therapies
- -
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Phase 3
Recruiting
- Conditions
- Essential Thrombocythemia
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06456346
- Locations
- 🇦🇷
Hospital Universitario Austral ( Site 0101), Pilar, Buenos Aires, Argentina
🇨🇱FALP-UIDO ( Site 0148), Santiago, Region M. De Santiago, Chile
🇩🇪VK&K Studien GbR ( Site 0370), Landshut, Bayern, Germany
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Phase 3
Recruiting
- Conditions
- Essential Thrombocythemia
- Interventions
- Drug: AnagrelideDrug: BomedemstatDrug: BusulfanDrug: Interferon alfa/pegylated interferon alfaDrug: Ruxolitinib
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06079879
- Locations
- 🇺🇸
Stanford Cancer Institute ( Site 0107), Stanford, California, United States
🇺🇸Roswell Park Cancer Institute ( Site 3421), Buffalo, New York, United States
🇺🇸University of Virginia ( Site 3422), Charlottesville, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath